Technology
Health
Biotechnology
Infinity Pharmaceuticals
$1.359876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.03 (-2.05%) Today
-$0.08 (-5.59%) After Hours
Why Robinhood?
You can buy or sell INFI and other stocks, options, ETFs, and crypto commission-free!
About
Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. Read More The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.
Employees
25
Headquarters
Cambridge, Massachusetts
Founded
1995
Market Cap
83.11M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
392.36K
High Today
$1.47
Low Today
$1.42
Open Price
$1.46
Volume
51.25K
52 Week High
$2.92
52 Week Low
$1.00
Collections
Technology
Health
Biotechnology
Biopharmaceutical
Cancer Prevention
Pharmaceutical
US
North America
News
Yahoo FinanceMay 10
Edited Transcript of INFI earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Infinity Pharmaceuticals Inc Earnings Call Cambridge May 10, 2019 (Thomson StreetEvents) -- Edited Transcript of Infinity Pharmaceuticals Inc earnings conference call or presentation Tuesday, May 7, 2019 at 8:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Adelene Q. Perkins Infinity Pharmaceuticals, Inc. - Chairman &...
NasdaqMay 8
Infinity (INFI) Earnings and Sales Miss Estimates in Q1
Infinity Pharmaceuticals Inc. INFI reported a loss of 24 cents in the first quarter of 2019, wider than a loss of 18 cents in the year-ago quarter. Loss was also wider than the Zacks Consensus Estimate of a loss of 5 cents. Revenues in the first quarter were $2.1 million, which mainly relates to the achievement of a $2-million milestone from PellePharm for the initiation of a phase III study, investigating patidegib (a hedgehog pathway inhibitor) in patients with Gorlin Syndrome. The company did not realiz...
Price Paid on Robinhood
33% Lower
Right Now
52 Week Low
$1.00
Average Price Paid
$2.03
52 Week High
$2.92
Earnings
-$0.25
-$0.09
$0.07
$0.23
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, After Hours